SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-019249
Filing Date
2020-04-28
Accepted
2020-04-28 16:28:58
Documents
5
Period of Report
2020-04-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20200428.htm 8-K 47936
2 EX-1.1 agle-ex11_7.htm EX-1.1 412400
3 EX-4.1 agle-ex41_8.htm EX-4.1 94199
4 EX-5.1 agle-ex51_6.htm EX-5.1 26439
5 GRAPHIC ggwjawdkumkd000001.jpg GRAPHIC 6939
  Complete submission text file 0001564590-20-019249.txt   591822
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 20825484
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences